Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Allopurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4B | O94953 | 2/20 | 0.43 |
| ▸ | KDM5C | P41229 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allopurinol SCHEMBL2565656 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL6142914 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL29793328 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL137085 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL7202471 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL28345614 | 0.96 | SMN1; SMN2 (0.92) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL9245971 | 0.89 | SMN1; SMN2 (0.80) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL2323594 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL3424532 | 0.85 | XDH (0.73) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| SCHEMBL11607575 | 0.83 | XDH (0.71) | SMN1; SMN2XDHLMNATSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 44137 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12640228-B2 | Polymorphic markers for pharmacogenetic HLA risk alleles | SEMA4 OPCO, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-12635917-B2 | Remote blood volume monitor | DAXOR CORP. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260138935-A1 | System and method for the production of chemical compounds and nutrient optimized fertilizer from animal waste products | Nalari Scientific, LLC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026106498-A1 | PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-21 | — | — | WO | claimed |
| EP-4744486-A1 | PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES. | NanoSanguis S.A. (PL) | 2026-05-20 | — | — | EP | claimed |
| EP-4744487-A1 | FLUID, METHODS OF PRODUCING FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-20 | — | — | EP | claimed |
| CN-122063206-A | Method for verifying uric acid reducing action mechanism of apocynum venetum leaf extract | 山东航空学院 | 2026-05-19 | — | — | CN | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | claimed |
| EP-0074909-B1 | COMPOSITIONS ON THE BASIS OF 5-HYDROXY-TRYPTOPHANE, MANUFACTURING PROCESS AND MEDICAMENTS CONTAINING THEM | S.A. PANMEDICA Société dite: (FR) | 1985-06-26 | — | — | EP | claimed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4478822-A | Drug delivery system utilizing thermosetting gels | MERCK & CO., INC. (US) | 1984-10-23 | — | — | US | claimed |
| US-4474752-A | DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4472387-A | 5-HYDROXYTRYPTOPHAN OR ESTER, NITROGEN HETEROCYCLE | PANMEDICA S.A. (FR) | 1984-09-18 | — | — | US | claimed |
| US-4426384-A | PYRAZOLO(3,4-D)PYRIMIDINES | Simoons, John R. A. (US) | 1984-01-17 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |